Organon & Co. (NYSE:OGN - Get Free Report) has been given a consensus rating of "Hold" by the five brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $18.00.
OGN has been the topic of a number of recent research reports. Morgan Stanley lowered their target price on Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Piper Sandler cut their price target on shares of Organon & Co. from $24.00 to $18.00 and set an "overweight" rating for the company in a report on Thursday, May 15th. Evercore ISI lowered Organon & Co. from an "outperform" rating to an "inline" rating in a research note on Friday, May 2nd. Finally, Barclays cut their target price on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th.
View Our Latest Stock Report on OGN
Insider Transactions at Organon & Co.
In related news, CFO Matthew M. Walsh purchased 11,400 shares of the firm's stock in a transaction on Monday, May 5th. The stock was purchased at an average cost of $8.82 per share, with a total value of $100,548.00. Following the completion of the purchase, the chief financial officer now owns 144,484 shares in the company, valued at approximately $1,274,348.88. This trade represents a 8.57% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kirke Weaver acquired 8,045 shares of the company's stock in a transaction dated Tuesday, May 6th. The shares were bought at an average price of $9.21 per share, for a total transaction of $74,094.45. Following the acquisition, the insider now directly owns 52,489 shares of the company's stock, valued at approximately $483,423.69. This trade represents a 18.10% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 102,345 shares of company stock worth $902,430. Company insiders own 1.96% of the company's stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Millstone Evans Group LLC bought a new stake in shares of Organon & Co. during the fourth quarter valued at approximately $29,000. Ransom Advisory Ltd acquired a new stake in Organon & Co. in the 1st quarter valued at $32,000. Larson Financial Group LLC increased its stake in Organon & Co. by 345.4% during the 4th quarter. Larson Financial Group LLC now owns 2,236 shares of the company's stock valued at $33,000 after purchasing an additional 1,734 shares in the last quarter. Riverview Trust Co raised its holdings in Organon & Co. by 117.7% during the fourth quarter. Riverview Trust Co now owns 2,390 shares of the company's stock worth $36,000 after buying an additional 1,292 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB raised its holdings in Organon & Co. by 32.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company's stock worth $41,000 after buying an additional 672 shares during the last quarter. Institutional investors own 77.43% of the company's stock.
Organon & Co. Trading Up 4.9%
Organon & Co. stock traded up $0.43 during trading hours on Friday, reaching $9.12. 6,116,678 shares of the company's stock traded hands, compared to its average volume of 3,256,912. The firm's 50 day moving average is $11.40 and its 200-day moving average is $13.97. Organon & Co. has a fifty-two week low of $8.01 and a fifty-two week high of $23.10. The firm has a market capitalization of $2.37 billion, a price-to-earnings ratio of 2.74, a PEG ratio of 0.90 and a beta of 0.75. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70.
Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $1.02 EPS for the quarter, topping the consensus estimate of $0.89 by $0.13. The business had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.53 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The firm's revenue was down 6.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.22 EPS. On average, analysts predict that Organon & Co. will post 3.68 earnings per share for the current year.
Organon & Co. Cuts Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, June 12th. Stockholders of record on Monday, May 12th will be paid a $0.02 dividend. The ex-dividend date of this dividend is Monday, May 12th. This represents a $0.08 annualized dividend and a dividend yield of 0.88%. Organon & Co.'s payout ratio is 2.78%.
Organon & Co. Company Profile
(
Get Free ReportOrganon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Featured Stories

Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.